S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28

OncoSec Medical Stock Forecast, Price & News

-0.07 (-8.62%)
(As of 06/30/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
34,677 shs
Average Volume
92,892 shs
Market Capitalization
$29.21 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Stock Forecast (MarketRank)

Overall MarketRank

1.76 out of 5 stars

Medical Sector

842nd out of 1,433 stocks

Pharmaceutical Preparations Industry

415th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
OncoSec Medical logo

About OncoSec Medical (NASDAQ:ONCS)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.

ONCS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$-45.17 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.97 per share


Free Float
Market Cap
$29.21 million
Not Optionable

OncoSec Medical Frequently Asked Questions

Should I buy or sell OncoSec Medical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoSec Medical stock.
View analyst ratings for OncoSec Medical
or view top-rated stocks.

What is OncoSec Medical's stock price forecast for 2022?

1 brokers have issued 1-year target prices for OncoSec Medical's stock. Their ONCS stock forecasts range from $5.00 to $5.00. On average, they expect OncoSec Medical's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 573.9% from the stock's current price.
View analysts' price targets for OncoSec Medical
or view top-rated stocks among Wall Street analysts.

How has OncoSec Medical's stock price performed in 2022?

OncoSec Medical's stock was trading at $0.9596 on January 1st, 2022. Since then, ONCS stock has decreased by 22.7% and is now trading at $0.7419.
View the best growth stocks for 2022 here

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our earnings forecast for OncoSec Medical

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) announced its quarterly earnings data on Tuesday, June, 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02.
View OncoSec Medical's earnings history

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

OncoSec Medical shares reverse split on the morning of Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the following people:
  • Mr. Robert J. DelAversano CPA, VP of Fin. and Principal Accounting Officer & Controller (Age 50, Pay $361.18k) (LinkedIn Profile)
  • Dr. Robert H. Arch Ph.D., Pres & CEO
  • Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 52)
  • Dr. Kim Jaffe, Assistant VP of Bus. Devel. & Operations
  • Mr. Tu Diep M.Sc., Sr. VP & Head of Operations
  • Dr. Sandra Aung Ph.D., Sr. VP & Chief Clinical Devel. Officer
  • Dr. Mai Hope Le M.D., Consultant (Age 46)

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical CEO Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among OncoSec Medical's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $0.74.

How much money does OncoSec Medical make?

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $29.21 million. The biotechnology company earns $-45.17 million in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does OncoSec Medical have?

OncoSec Medical employs 54 workers across the globe.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for OncoSec Medical is www.oncosec.com. The biotechnology company can be reached via phone at (858) 662-6732, via email at [email protected], or via fax at 858-430-3832.

This page (NASDAQ:ONCS) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.